Lung cancer is the worldwide most widespread tumor disease with very poor prognosis. It is the most frequent cause of death on a malignancy. Surgery remains the treatment of choice, however, it can be applied to a small number of patients who are at the time of diagnosis in the operable stage. Chemoradiotherapy can be used either as an exclusive or as a neoadjuvant treatment. This paper reviews chemoradiotherapy regiments in those two clinical situations. With exclusive chemoradiotherapy, the concomitant scheme seems to be the most favourable.

Klinika komplexní onkologické péce oddĕlení radiacní inkologie Masarykův onkologický ústav Brno